Results 321 to 330 of about 1,501,016 (387)

Luspatercept versus mitapivat for non-transfusion-dependent β-thalassemia: Dare to compare? [PDF]

Hemasphere
Musallam KM, Sheth S, Cappellini MD, Kuo KHM, Kattamis A, Aydinok Y, Viprakasit V, Taher AT.   +7 more
europepmc   +1 more source

Exploring the Association Between Intra‐Patient Variability in Trough Concentration of Pazopanib and Clinical Outcomes in Renal Cell Carcinoma and Soft Tissue Sarcoma Patients

Clinical Pharmacology &Therapeutics, EarlyView.
Pazopanib is an oral tyrosine kinase inhibitor used in patients with either metastatic renal cell carcinoma or soft tissue sarcoma. Pazopanib has a high interindividual variability in pharmacokinetics and pharmacodynamics and a well‐established exposure–response relationship. Therefore, therapeutic drug monitoring is recommended to improve the efficacy–
Amy Rieborn, Eline L. Giraud, Teun van Gelder, Hans Gelderblom, Nielka P. van Erp, Tom van der Hulle, Dirk Jan A. R. Moes   +6 more
wiley   +1 more source

Navigating the Real World: A Scoping Review of Structured Frameworks to Effectively Identify, Evaluate, and Select Real‐World Data Sources for Fit‐for‐Purpose Studies

Clinical Pharmacology &Therapeutics, EarlyView.
The potential of real‐world data (RWD), particularly from patient registries, has been increasingly recognized over the last decade by academia, regulators, and health technology assessment (HTA) bodies for its role in assessing a product's effectiveness and supporting regulatory submissions.
Sonia Zebachi, Julien Tanniou, Elisabeth Bakker, Sieta T. de Vries, Rossella Di Bidino, Entela Xoxi, Anna Glaser, Gianluigi Savarese, Jan Hillert, Peter G. M. Mol, Kelly Plueschke, Billy Amzal, Ghinwa Y. Hayek, Jeverson Moreira   +13 more
wiley   +1 more source

Post hoc analysis of a randomized placebo-controlled trial suggests potential visual benefits of branched-chain amino acids in retinitis pigmentosa. [PDF]

Sci Rep
Hasegawa T, Ikeda HO, Abe H, Amino Y, Nakagawa T, Tada H, Miyata M, Oishi A, Morita S, Tsujikawa A.   +9 more
europepmc   +1 more source

Pharmacogenetic Implementation Studies—Lessons Learned From the PREPARE Study

Clinical Pharmacology &Therapeutics, EarlyView.
The Ubiquitous Pharmacogenomics consortium (www.upgx.eu) has recently completed and published the Preemptive Pharmacogenomic Testing for Preventing Adverse Drug Reactions (PREPARE) study on the implementation of panel‐based pharmacogenetic testing. PREPARE has provided interesting lessons for the design, execution, and interpretation of future clinical
Henk‐Jan Guchelaar, Cathelijne H. van der Wouden, Lisanne E. N. Manson, Heshu Abdullah‐Koolmees, Kathrin Blagec, Tanja Blagus, Stefan Böhringer, Erika Cecchin, Ka‐Chun Cheung, Vera H. M. Deneer, Siv Jonsson, Candace Joefield‐Roka, Katja S. Just, Mats O. Karlsson, Lidija Konta, Rudolf Koopmann, Marjolein Kriek, Thorsten Lehr, Christina Mitropoulou, Victoria Rollinson, Rossana Roncato, Matthias Samwald, Elke Schaeffeler, Maria Skokou, Matthias Schwab, Daniela Steinberger, Julia C. Stingl, Roman Tremmel, Richard M. Turner, Mandy H. van Rhenen, Cristina L. Dávila‐Fajardo, Vita Dolžan, George P. Patrinos, Munir Pirmohamed, Gere Sunder‐Plassmann, Giuseppe Toffoli, Jesse J. Swen, Ubiquitous Pharmacogenomics Consortium   +37 more
wiley   +1 more source

Brexanolone, zuranolone and related neurosteroid GABA_A receptor positive allosteric modulators for postnatal depression. [PDF]

Cochrane Database Syst Rev
Wilson CA, Robertson L, Ayre K, Hendon JL, Dawson S, Bridges C, Khalifeh H.   +6 more
europepmc   +1 more source

A Pharmacometric Method for Quantitative Determination of Improvement in Body Composition and Characterization of the Exposure–Response Relationship during Treatment of Obesity with Tirzepatide

Clinical Pharmacology &Therapeutics, EarlyView.
About half of the world's population is living with overweight or obesity. Tirzepatide is an approved treatment for chronic weight management. We sought to characterize the exposure–response relationship for weight reduction in patients with overweight or obesity and quantify the associated changes in body composition.
Emmanuel Chigutsa, Lucy Her, Xiaosu Ma, Shweta Urva, Karen Schneck   +4 more
wiley   +1 more source

Patient-Reported Outcomes for Glabellar Line Improvement and Satisfaction With the RelabotulinumtoxinA Ready-to-Use Liquid Formulation: Data From the Phase 3 READY-1 Trial. [PDF]

Aesthet Surg J
Gold MH, Donofrio L, Shridharani S, Moradi A, Biesman B, Chiang M, George R, Polder K, Solish N, Schwarcz R, Berg AK, Weinberg F, Axén E.   +12 more
europepmc   +1 more source

Continuous Intravenous Nimodipine Infusion With Ethanol as Carrier in Aneurysmal Subarachnoid Hemorrhage Does Not Result in Measurable Cerebral Ethanol Levels

Clinical Pharmacology &Therapeutics, EarlyView.
An unimpaired neurological evaluation is essential for detecting delayed cerebral ischemia (DCI) in aneurysmal subarachnoid hemorrhage (aSAH) patients. Nimodipine is currently the only drug approved for DCI prevention. Intravenous nimodipine infusion contains 23.7 vol% ethanol as an excipient, resulting in up to 45 g of ethanol being infused daily ...
Miriam M. Moser, Karl Rössler, Dorian Hirschmann, Leon Gramss, Walter Plöchl, Johannes Herta, Andrea Reinprecht, Markus Zeitlinger, Arthur Hosmann   +8 more
wiley   +1 more source

Placebo

Forum Médical Suisse ‒ Swiss Medical Forum, 2007
openaire   +1 more source